First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial
Peking University · Peking University Cancer Hospital · +93 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
77
total citations
- FWCI
- 86.37
- Percentile
- 100%
- References
- 35
Citations per year
Authors
90- LSLin ShenCorresponding
Peking University, Peking University Cancer Hospital
- YZYanqiao Zhang
Harbin Medical University, Third Affiliated Hospital of Harbin Medical University
- ZLZiyu Li
Peking University, Peking University Cancer Hospital
- XZXiaotian Zhang
Peking University, Peking University Cancer Hospital, Northern Jiangsu People's Hospital
- XGXiangyu Gao
Peking University, Peking University Cancer Hospital
Topics & keywords
Topics
Keywords
- Gastroesophageal Junction
- Gastric adenocarcinoma
- Chemotherapy
- Medicine
- Double blind
- Internal medicine
- Gastroenterology
- Adenocarcinoma
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.